These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 23472599)

  • 1. Adiponectin and endothelial markers in postmenopausal women taking oral or transdermal hormone therapy.
    Ruszkowska B; Sokup A; Kulwas A; Kwapisz J; Góralczyk K; Socha MW; Rhone P; Rość D
    Acta Obstet Gynecol Scand; 2013 Jul; 92(7):841-6. PubMed ID: 23472599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women.
    Vehkavaara S; Silveira A; Hakala-Ala-Pietilä T; Virkamäki A; Hovatta O; Hamsten A; Taskinen MR; Yki-Järvinen H
    Thromb Haemost; 2001 Apr; 85(4):619-25. PubMed ID: 11341495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced expression of endothelial cell markers after long-term transdermal hormone replacement therapy in women with coronary artery disease.
    Seljeflot I; Arnesen H; Hofstad AE; Os I
    Thromb Haemost; 2000 Jun; 83(6):944-8. PubMed ID: 10896253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
    Zegura B; Guzic-Salobir B; Sebestjen M; Keber I
    Menopause; 2006; 13(4):643-50. PubMed ID: 16837886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of oral and transdermal short-term estrogen therapy in postmenopausal women with metabolic syndrome.
    Chu MC; Cosper P; Nakhuda GS; Lobo RA
    Fertil Steril; 2006 Dec; 86(6):1669-75. PubMed ID: 17074346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased levels of C-reactive protein after oral hormone replacement therapy may not be related to an increased inflammatory response.
    Silvestri A; Gebara O; Vitale C; Wajngarten M; Leonardo F; Ramires JA; Fini M; Mercuro G; Rosano GM
    Circulation; 2003 Jul; 107(25):3165-9. PubMed ID: 12796135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of hormone therapy on soluble cell adhesion molecules in postmenopausal women with coronary artery disease.
    Yeboah J; Klein K; Brosnihan B; Reboussin D; Herrington DM
    Menopause; 2008; 15(6):1060-4. PubMed ID: 18521047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of ghrelin and leptin receptor levels in postmenopausal women who received oral or transdermal menopausal hormonal therapy.
    Ruszkowska B; Sokup A; Kulwas A; Socha MW; Góralczyk K; Góralczyk B; Rość D
    J Zhejiang Univ Sci B; 2012 Jan; 13(1):35-42. PubMed ID: 22205618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic syndrome in postmenopausal women: the influence of oral or transdermal estradiol on inflammation and coagulation markers.
    Chu MC; Cushman M; Solomon R; Lobo RA
    Am J Obstet Gynecol; 2008 Nov; 199(5):526.e1-7. PubMed ID: 18511016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of transdermal and oral postmenopausal hormone therapy on vascular function: a randomized, placebo-controlled study in healthy postmenopausal women.
    Hemelaar M; van der Mooren MJ; van Baal WM; Schalkwijk CG; Kenemans P; Stehouwer CD
    Menopause; 2005; 12(5):526-35. PubMed ID: 16145306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of circulating cellular adhesion molecules with menopausal status and hormone replacement therapy. Time-dependent change in transdermal, but not oral estrogen users.
    Oger E; Alhenc-Gelas M; Plu-Bureau G; Mennen L; Cambillau M; Guize L; Pujol Y; Scarabin P
    Thromb Res; 2001 Jan; 101(2):35-43. PubMed ID: 11342204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of transdermal hormone replacement therapy on the monocyte chemoattractant protein-1 concentrations and other vascular inflammatory markers and on endothelial function in postmenopausal women.
    Sumino H; Ichikawa S; Ohyama Y; Takahashi T; Saito Y; Nakamura T; Kanda T; Kurabayashi M
    Am J Cardiol; 2005 Jul; 96(1):148-53. PubMed ID: 15979455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triglycerides as an early pathophysiological marker of endothelial dysfunction in nondiabetic women with a previous history of gestational diabetes.
    Sokup A; Góralczyk B; Góralczyk K; Rość D
    Acta Obstet Gynecol Scand; 2012 Feb; 91(2):182-8. PubMed ID: 21954994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose continuous combinations of hormone therapy and biochemical surrogate markers for vascular tone and inflammation: transdermal versus oral application.
    Mueck AO; Genazzani AR; Samsioe G; Vukovic-Wysocki I; Seeger H
    Menopause; 2007; 14(6):978-84. PubMed ID: 17595593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of transdermal hormone replacement therapy on levels of soluble P- and E-selectin in postmenopausal healthy women.
    Farzati A; Esposito K; Colacurci N; Fornaro F; Chiantera V; Farzati B
    Fertil Steril; 2002 Mar; 77(3):476-80. PubMed ID: 11872198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids.
    Rozenberg S; Ylikorkala O; Arrenbrecht S
    Int J Fertil Womens Med; 1997; 42 Suppl 2():376-87. PubMed ID: 9397385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effects of oral and transdermal hormone replacement therapy on plasma homocysteine levels.
    Chiantera V; Sarti CD; Fornaro F; Farzati A; De Franciscis P; Sepe E; Borrelli AL; Colacurci N
    Menopause; 2003; 10(4):286-91. PubMed ID: 12851511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
    Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
    Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of oral and transdermal estrogen therapies on circulating cytokines and chemokines in postmenopausal women with hysterectomy.
    Yasui T; Saijo A; Uemura H; Matsuzaki T; Tsuchiya N; Yuzurihara M; Kase Y; Irahara M
    Eur J Endocrinol; 2009 Aug; 161(2):267-73. PubMed ID: 19451213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of oral conjugated equine estrogen and transdermal estrogen on atherosclerotic vascular disease risk markers and endothelial function in healthy postmenopausal women.
    Ho JY; Chen MJ; Sheu WH; Yi YC; Tsai AC; Guu HF; Ho ES
    Hum Reprod; 2006 Oct; 21(10):2715-20. PubMed ID: 16807281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.